• Explore /
  • Poster
  • / Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Abstract Poster

Authors

Daniel Petrylak

Daniel Peter Petrylak

Columbia University Medical Center, New York, NY

Daniel Peter Petrylak , Philip W. Kantoff , Anthony E. Mega , Nicholas J. Vogelzang , Joe Stephenson Jr., Mark T. Fleming , Nancy Stambler , Michaela Petrini , Kathleen Huang , Robert Joseph Israel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01414283

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 119)

DOI

10.1200/jco.2013.31.6_suppl.119

Abstract #

119

Poster Bd #

H2

Abstract Disclosures

Similar Posters

First Author: Daniel Peter Petrylak

First Author: Daniel Peter Petrylak

First Author: Ronan Flippot

First Author: Jones T. Nauseef